Skip to main content

Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries

Molecular Biology Reports volume 41, pages 4713–4720 (2014)Cite this article

Abstract

In-stent restenosis (ISR) remains the most common complication of percutaneous coronary intervention. Due to shared risk factors, it is postulated that non-alcoholic fatty liver disease (NAFLD) patients have an increased risk of ISR. This study aimed to determine the association between NAFLD and ISR in patients after bare metal stenting. This study included a cohort of 210 consecutive patients (150 men and 60 women) undergoing follow-up angiography. The primary end-point was angiographic ISR. Multivariate logistic regression analysis was used to identify independent risk factors for ISR. The cumulative ISR rate during follow-up was analyzed by Kaplan–Meier method. Subgroup analyses were also done for different gender. The ISR rate was 29.5 %. Patients with NAFLD had a significantly higher prevalence of ISR than patients without NAFLD (43.3 vs. 16.0 %, P < 0.001). In logistic regression analysis, NAFLD was associated with increased ISR, independent of low-density lipoprotein cholesterol, body mass index (adjusted odds ratio: 2.688, 95 % confidence intervals: 1.285–5.537, P < 0.001). Male NAFLD patients had a higher prevalence of ISR than patients without NAFLD (48.4 vs. 15.3 %, P < 0.001), while the prevalence of ISR in female patients with and without NAFLD were comparable (7.7 vs. 17.0 %, P = 0.404). Kaplan–Meier analysis showed a significant association between NAFLD and ISR in all patients (log-rank P = 0.008) and in male subgroup (log-rank P = 0.033), but not in female subgroup (log-rank P = 0.313). This preliminary study suggests that NAFLD could independently associate with a high prevalence of ISR, especially in male patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

Abbreviations

BMI:

Body mass index

CI:

Confidence intervals

CVD:

Cardiovascular disease

HDL:

High density lipoprotein

ISR:

In-stent restenosis

LDL:

Low density lipoprotein

NAFLD:

Non-alcoholic fatty liver disease

OR:

Odds ratios

PCI:

Percutaneous coronary intervention

References

  1. Fan JG, Farrell GC (2009) Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 50:204–210

    Article  PubMed  Google Scholar 

  2. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140:124–131

    Article  PubMed  Google Scholar 

  3. David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB (2009) Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 49:1904–1912

    PubMed Central  Article  PubMed  Google Scholar 

  4. Utzschneider KM, Kahn SE (2006) Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 91:4753–4761

    CAS  Article  PubMed  Google Scholar 

  5. Kasturiratne A, Weerasinghe S, Dassanayake AS, Rajindrajith S, de Silva AP, Kato N, Wickremasinghe AR, de Silva HJ (2012) Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol 28(1):142–147

    Article  Google Scholar 

  6. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923

    Article  PubMed  Google Scholar 

  7. Targher G, Arcaro G (2007) Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 191:235–240

    CAS  Article  PubMed  Google Scholar 

  8. Bonora E, Targher G (2012) Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 9:372–381

    CAS  Article  PubMed  Google Scholar 

  9. Targher G, Chonchol M, Pichiri I, Zoppini G (2011) Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? J Endocrinol Invest 34:544–551

    CAS  PubMed  Google Scholar 

  10. Wong VW, Wong GL, Yip GW, Lo AO, Limquiaco J, Chu WC, Chim AM, Yu CM, Yu J, Chan FK et al (2011) Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 60:1721–1727

    CAS  Article  PubMed  Google Scholar 

  11. Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363:1341–1350

    CAS  Article  PubMed  Google Scholar 

  12. Sun Z, Almutairi AM (2010) Diagnostic accuracy of 64 multislice CT angiography in the assessment of coronary in-stent restenosis: a meta-analysis. Eur J Radiol 73:266–273

    Article  PubMed  Google Scholar 

  13. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller KM (2000) Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 35:157–163

    CAS  Article  PubMed  Google Scholar 

  14. Desouza CV, Hamel FG, Bidasee K, O’Connell K (2011) Role of inflammation and insulin resistance in endothelial progenitor cell dysfunction. Diabetes 60:1286–1294

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  15. Kuwano T, Miura S, Shirai K, Ike A, Mori K, Shimizu T, Zhang B, Iwata A, Nishikawa H, Kawamura A et al (2011) Serum levels of bilirubin as an independent predictor of coronary in-stent restenosis: a new look at an old molecule. J Atheroscler Thromb 18:574–583

    CAS  Article  PubMed  Google Scholar 

  16. Obika M, Noguchi H (2012) Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012:145754

    PubMed Central  Article  PubMed  Google Scholar 

  17. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084–1089

    CAS  Article  PubMed  Google Scholar 

  18. Mazeika P, Prasad N, Bui S, Seidelin PH (2003) Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 145:1013–1021

    Article  PubMed  Google Scholar 

  19. Huang Y, Bi Y, Xu M, Ma Z, Xu Y, Wang T, Li M, Liu Y, Lu J, Chen Y et al (2012) Nonalcoholic Fatty liver disease is associated with atherosclerosis in middle-aged and elderly chinese. Arterioscler Thromb Vasc Biol 32:2321–2326

    CAS  Article  PubMed  Google Scholar 

  20. Jornayvaz FR, Samuel VT, Shulman GI (2010) The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. Annu Rev Nutr 30:273–290

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  21. Polyzos SA, Kountouras J, Deretzi G, Zavos C, Mantzoros CS (2012) The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease. Curr Mol Med 12:68–82

    CAS  Article  PubMed  Google Scholar 

  22. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS (2004) Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27:2654–2660

    CAS  Article  PubMed  Google Scholar 

  23. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  24. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M et al (2005) Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90:3498–3504

    CAS  Article  PubMed  Google Scholar 

  25. Kamishirado H, Inoue T, Sakuma M, Tsuda T, Hayashi T, Takayanagi K, Node K (2007) Effects of statins on restenosis after coronary stent implantation. Angiology 58:55–60

    CAS  Article  PubMed  Google Scholar 

  26. Rana JS, Mittleman MA, Ho KK, Cutlip DE (2005) Obesity and clinical restenosis after coronary stent placement. Am Heart J 150:821–826

    Article  PubMed  Google Scholar 

  27. Mehilli J, Kastrati A, Bollwein H, Dibra A, Schuhlen H, Dirschinger J, Schomig A (2003) Gender and restenosis after coronary artery stenting. Eur Heart J 24:1523–1530

    Article  PubMed  Google Scholar 

  28. Bernelot Moens SJ, Schnitzler GR, Nickerson M, Guo H, Ueda K, Lu Q, Aronovitz MJ, Nickerson H, Baur WE, Hansen U et al (2012) Rapid estrogen receptor signaling is essential for the protective effects of estrogen against vascular injury. Circulation 126(16):1993–2004

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  29. Novella S, Laguna-Fernandez A, Lazaro-Franco M, Sobrino A, Bueno-Beti C, Tarin JJ, Monsalve E, Sanchis J, Hermenegildo C (2012). Estradiol, acting through estrogen receptor alpha, restores dimethylarginine dimethylaminohydrolase activity and nitric oxide production in oxLDL-treated human arterial endothelial cells. Mol Cell Endocrinol

  30. Vavra AK, Havelka GE, Martinez J, Lee VR, Fu B, Jiang Q, Keefer LK, Kibbe MR (2011) Insights into the effect of nitric oxide and its metabolites nitrite and nitrate at inhibiting neointimal hyperplasia. Nitric Oxide 25:22–30

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  31. El-Koofy N, El-Karaksy H, El-Akel W, Helmy H, Anwar G, El-Sayed R, El-Hennawy A (2012) Ultrasonography as a non-invasive tool for detection of nonalcoholic fatty liver disease in overweight/obese Egyptian children. Eur J Radiol 81:3120–3123

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the Scientific Research Foundation of Wenzhou, Zhejiang Province, China (H20090014, Y20090269), Health Bureau of Zhejiang Province (2010KYB070), Research Foundation of Education Bureau of Zhejiang Province (Y201009942), Fresh Talent Program for Science and Technology Department of Zhejiang Province (2013R413018, 2013R413035 and 2013R413015), Research Funds for Tian Qing Liver Diseases (TQGB20120057) and Project of New Century 551 Talent Nurturing in Wenzhou.

Conflict of interest

No.

Author information

Affiliations

  1. Department of Infection and Liver Diseases, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue lane, Wenzhou, 325000, China

    Ke-Qing Shi, Fa-Ling Wu, Wen-Yue Liu, Chen-Chen Zhao, Xian-Feng Lin, Yong-Ping Chen & Ming-Hua Zheng

  2. Institute of Hepatology, Wenzhou Medical University, No. 2 Fuxue lane, Wenzhou, 325000, China

    Ke-Qing Shi, Fa-Ling Wu, Yong-Ping Chen & Ming-Hua Zheng

  3. School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China

    Wen-Yue Liu & Chen-Chen Zhao

  4. Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

    Chang-Xi Chen & Sheng-Jie Wu

  5. Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

    Yao-Yao Xie

  6. Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China

    Xian-Feng Lin

  7. Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China

    Danny Ka-Ho Wong & Man-Fung Yuen

  8. State Key Laboratory for Liver Research, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China

    Man-Fung Yuen

Authors
  1. Ke-Qing Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fa-Ling Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wen-Yue Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chen-Chen Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chang-Xi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yao-Yao Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sheng-Jie Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xian-Feng Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yong-Ping Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Danny Ka-Ho Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Man-Fung Yuen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ming-Hua Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming-Hua Zheng.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Shi, KQ., Wu, FL., Liu, WY. et al. Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries. Mol Biol Rep 41, 4713–4720 (2014). https://doi.org/10.1007/s11033-014-3342-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-014-3342-z

Keywords

  • Non-alcoholic fatty liver disease
  • In-stent restenosis
  • Bare metal stent
  • Angiography